Lawrence R. Soma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lawrence R. Soma has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
C. E. Uboh
University of Pennsylvania, School of Veterinary Medicine, New Bolton Center Campus, Kennett Square, PA; USA
5 shared publications- Jin-Wen Chen
Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348, United States
4 shared publications - Mary A. Robinson
Department of Clinical Studies–New Bolton Center, University of Pennsylvania, Kennett Square, PA, USA
4 shared publications Raymond C. Boston
Department of Clinical Studies – New Bolton Center University of Pennsylvania School of Veterinary Medicine Kennett Square PA USA
4 shared publications- Youwen You
Department of Clinical Studies—New Bolton Center, School of Veterinary Medicine University of Pennsylvania Kennett Pennsylvania USA
4 shared publications Cornelius E. Uboh
3 shared publications
Latest Publications
- Open Access
- 23 December 2024
- Published by Elsevier in Veterinary Immunology and Immunopathology
- Vol. 280, 110868
Positive correlation between interleukin (IL) 1 beta to IL-1 receptor antagonist levels in Standardbred racehorses prior to racing
- 23 December 2024
- Published by Elsevier in Veterinary Immunology and Immunopathology
- Vol. 280, 110868
Open AccessPositive correlation between interleukin (IL) 1 beta to IL-1 receptor antagonist levels in Standardbred racehorses prior to racing
- 18 May 2021
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (5) , 973-982
Gene transcripts expressed in equine white blood cells are potential biomarkers of extracorporeal shock wave therapy
Extracorporeal shockwave therapy (ESWT) is a treatment applied to musculoskeletal injuries in equine athletes to alleviate pain and accelerate healing. ESWT also causes acute tissue damage. Therefore, its ability to act as an analgesic and cause tissue damage potentially increases the risk of a catastrophic event if used shortly before a strenuous competition such as horseracing. While ESWT is prohibited by many racing jurisdictions within 10 days prior to competition, a test to detect whether a horse has received ESWT is needed. ESWT changes the protein levels of inflammatory mediators in blood, and white blood cells (WBC) typically produce these proteins. Changes in gene expression precede changes in protein production; thus, it was hypothesized that WBC gene transcripts might serve as biomarkers of ESWT. To test this hypothesis, six thoroughbred horses received a single administration of ESWT to the distal limb, and WBC RNA was extracted from blood samples collected before (0 h) and after ESWT (2, 4, 6, 24, 48, and 72 h). Targeted and untargeted analyses evaluated the transcriptome using quantitative PCR (qPCR) and microarray. The expression of IL‐1α, IL‐1β, TNF‐α, IL‐1Ra1, IL‐1Ra2 and TGF‐β1, and BMPR1A in circulating WBCs was significantly up‐regulated, while IFN‐γ, ZNF483, TMEM80, CAH6, ENPP, and S8723 were significantly down‐regulated at various time points following ESWT. These data support the hypothesis that changes in WBC gene transcripts could serve as biomarkers for ESWT.
- 18 May 2021
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (5) , 973-982
Gene transcripts expressed in equine white blood cells are potential biomarkers of extracorporeal shock wave therapy
Extracorporeal shockwave therapy (ESWT) is a treatment applied to musculoskeletal injuries in equine athletes to alleviate pain and accelerate healing. ESWT also causes acute tissue damage. Therefore, its ability to act as an analgesic and cause tissue damage potentially increases the risk of a catastrophic event if used shortly before a strenuous competition such as horseracing. While ESWT is prohibited by many racing jurisdictions within 10 days prior to competition, a test to detect whether a horse has received ESWT is needed. ESWT changes the protein levels of inflammatory mediators in blood, and white blood cells (WBC) typically produce these proteins. Changes in gene expression precede changes in protein production; thus, it was hypothesized that WBC gene transcripts might serve as biomarkers of ESWT. To test this hypothesis, six thoroughbred horses received a single administration of ESWT to the distal limb, and WBC RNA was extracted from blood samples collected before (0 h) and after ESWT (2, 4, 6, 24, 48, and 72 h). Targeted and untargeted analyses evaluated the transcriptome using quantitative PCR (qPCR) and microarray. The expression of IL‐1α, IL‐1β, TNF‐α, IL‐1Ra1, IL‐1Ra2 and TGF‐β1, and BMPR1A in circulating WBCs was significantly up‐regulated, while IFN‐γ, ZNF483, TMEM80, CAH6, ENPP, and S8723 were significantly down‐regulated at various time points following ESWT. These data support the hypothesis that changes in WBC gene transcripts could serve as biomarkers for ESWT.
- 11 December 2020
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 44 (3) , 349-358
Bayesian‐based withdrawal estimates using pharmacokinetic parameters for two capsaicinoid‐containing products administered to horses
Capsaicinoids deter horses from chewing on bandages and are applied topically to provide analgesia to musculoskeletal injuries. They are banned during competition due to their nerve blocking properties. The pharmacokinetics of oral (PO) and direct gastric administration via nasogastric tube (NG), or topical (TOP) administration of two capsaicinoid‐containing products were investigated, and the withdrawal times required prior to competition were estimated. Capsaicin (CAP) and dihydrocapsaicin (DCAP) were quantified in plasma, and both compounds were best described by a delayed absorption two compartment elimination model following PO administration and by a first order absorption one compartment elimination model following TOP administration. Capsaicin and DCAP could not be quantified in most samples following NG administration. Following PO administration, the time to maximum plasma concentration (Tmax) for CAP and DCAP was 0.25 (0.08–0.50) hr. Following TOP application, the Tmax for CAP and DCAP was 4 (2–6) and 5 (3–12) hr, respectively. By 8 hr post‐PO administration and 36 hr post‐TOP application, CAP and DCAP were below the lower limit of quantification. Capsaicin and DCAP were not detected in urine samples. Withdrawal times were predicted using the 99.99% credibility interval limits of the pharmacokinetic parameters calculated with Bayesian estimation.
- 11 December 2020
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 44 (3) , 349-358
Bayesian‐based withdrawal estimates using pharmacokinetic parameters for two capsaicinoid‐containing products administered to horses
Capsaicinoids deter horses from chewing on bandages and are applied topically to provide analgesia to musculoskeletal injuries. They are banned during competition due to their nerve blocking properties. The pharmacokinetics of oral (PO) and direct gastric administration via nasogastric tube (NG), or topical (TOP) administration of two capsaicinoid‐containing products were investigated, and the withdrawal times required prior to competition were estimated. Capsaicin (CAP) and dihydrocapsaicin (DCAP) were quantified in plasma, and both compounds were best described by a delayed absorption two compartment elimination model following PO administration and by a first order absorption one compartment elimination model following TOP administration. Capsaicin and DCAP could not be quantified in most samples following NG administration. Following PO administration, the time to maximum plasma concentration (Tmax) for CAP and DCAP was 0.25 (0.08–0.50) hr. Following TOP application, the Tmax for CAP and DCAP was 4 (2–6) and 5 (3–12) hr, respectively. By 8 hr post‐PO administration and 36 hr post‐TOP application, CAP and DCAP were below the lower limit of quantification. Capsaicin and DCAP were not detected in urine samples. Withdrawal times were predicted using the 99.99% credibility interval limits of the pharmacokinetic parameters calculated with Bayesian estimation.
- 18 May 2020
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 43 (6) , 557-564
Pharmacokinetics of xylazine after 2‐, 4‐, and 6‐hr durations of continuous rate infusions in horses
Intravenous (i.v.) bolus administration of xylazine (XYL) (0.5 mg/kg) immediately followed by a continuous rate infusion (CRI) of 1 mg kg−1 hr−1 for 2, 4, and 6 hr produced immediate sedation, which lasted throughout the duration of the CRI. Heart rate decreased and blood pressure increased significantly (p > .05) in all horses during the first 15 min of infusion, both returned to and then remained at baseline during the duration of the infusion. Compartmental models were used to investigate the pharmacokinetics of XYL administration. Plasma concentration–time curves following bolus and CRI were best described by a one‐compartment model. No differences were found between pharmacokinetic estimates of the CRIs for the fractional elimination rate constant (Ke), half‐life (t1/2e), volume of distribution (Vd), and clearance (Cl). Median and range were 0.42 (0.15–0.97)/hr, 1.68 (0.87–4.52) hr, 5.85 (2.10–19.34) L/kg, and 28.7 (19.6–39.5) ml min−1 kg−1, respectively. Significant differences were seen for area under the curve ( ) (p < .0002) and maximum concentration (Cmax) (p < .04). This indicates that with increasing duration of infusion, XYL may not accumulate in a clinically relevant way and hence no adjustments are required in a longer XYL CRI to maintain a constant level of sedation and a rapid recovery.
- 18 May 2020
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 43 (6) , 557-564
Pharmacokinetics of xylazine after 2‐, 4‐, and 6‐hr durations of continuous rate infusions in horses
Intravenous (i.v.) bolus administration of xylazine (XYL) (0.5 mg/kg) immediately followed by a continuous rate infusion (CRI) of 1 mg kg−1 hr−1 for 2, 4, and 6 hr produced immediate sedation, which lasted throughout the duration of the CRI. Heart rate decreased and blood pressure increased significantly (p > .05) in all horses during the first 15 min of infusion, both returned to and then remained at baseline during the duration of the infusion. Compartmental models were used to investigate the pharmacokinetics of XYL administration. Plasma concentration–time curves following bolus and CRI were best described by a one‐compartment model. No differences were found between pharmacokinetic estimates of the CRIs for the fractional elimination rate constant (Ke), half‐life (t1/2e), volume of distribution (Vd), and clearance (Cl). Median and range were 0.42 (0.15–0.97)/hr, 1.68 (0.87–4.52) hr, 5.85 (2.10–19.34) L/kg, and 28.7 (19.6–39.5) ml min−1 kg−1, respectively. Significant differences were seen for area under the curve ( ) (p < .0002) and maximum concentration (Cmax) (p < .04). This indicates that with increasing duration of infusion, XYL may not accumulate in a clinically relevant way and hence no adjustments are required in a longer XYL CRI to maintain a constant level of sedation and a rapid recovery.
- 10 September 2019
- Published by Wiley in Equine Veterinary Journal
- Vol. 52 (3) , 449-454
Inflammatory mediators are potential biomarkers for extracorporeal shockwave therapy in horses
Summary: Background: Extracorporeal shockwave therapy (ESWT) can potentially mask painful injuries in equine athletes. Tests to detect whether a horse has received ESWT prior to competition are needed. Extracorporeal shockwave therapy is known to affect inflammatory mediators in other species, and if these mediators are altered in the horse, these could serve as biomarkers of ESWT. Objectives: To test the hypothesis that a single application of ESWT will alter the circulating protein concentrations of 10 inflammatory mediators in horse plasma. Study design: Prospective repeated measures experimental study. Methods: Eleven healthy horses were administered a single dose of ESWT on the dorsal surface of proximal MCIII. Blood samples were collected at −168, −144, −120, −96, −72, −70, −68, −66, −48, −24, −6, −4, −2, 0 h before and 2, 4, 6, 24, 48, 72, 96, 168, 336 and 504 h after ESWT. Plasma concentrations of interleukin 1 beta (IL‐1β), IL‐1 receptor antagonist (IL‐1RA), IL‐2, IL‐4, IL‐6, IL‐10, IL‐15, interferon gamma (IFN‐γ), soluble toll‐like receptor 2 (sTLR2) and tumour necrosis factor alpha (TNF‐α) were measured to assess the effects of ESWT on these mediators. Results: Baseline concentrations of inflammatory mediators did not change substantially during the week prior to ESWT. Plasma concentrations of five inflammatory factors changed following ESWT. IL‐1β and IL‐6 were significantly down‐regulated (P<0.01), while TNF‐α, IL‐1RA and TLR2 were significantly up‐regulated (P<0.01). The remaining cytokines were not significantly affected by ESWT. Main limitations: This study was performed in a small number of sedentary, healthy pasture‐kept horses using a single dose of ESWT applied to a single location. Additional studies are necessary to determine the effect of ESWT on inflammatory mediators in athletic horses undergoing treatment for musculoskeletal injuries. Conclusions: Plasma concentrations of TNF‐α, IL‐1β, IL‐1RA, IL‐6 and TLR2 were significantly affected by ESWT, and deserve further investigation as possible biomarkers of ESWT.
- 10 September 2019
- Published by Wiley in Equine Veterinary Journal
- Vol. 52 (3) , 449-454
Inflammatory mediators are potential biomarkers for extracorporeal shockwave therapy in horses
Summary: Background: Extracorporeal shockwave therapy (ESWT) can potentially mask painful injuries in equine athletes. Tests to detect whether a horse has received ESWT prior to competition are needed. Extracorporeal shockwave therapy is known to affect inflammatory mediators in other species, and if these mediators are altered in the horse, these could serve as biomarkers of ESWT. Objectives: To test the hypothesis that a single application of ESWT will alter the circulating protein concentrations of 10 inflammatory mediators in horse plasma. Study design: Prospective repeated measures experimental study. Methods: Eleven healthy horses were administered a single dose of ESWT on the dorsal surface of proximal MCIII. Blood samples were collected at −168, −144, −120, −96, −72, −70, −68, −66, −48, −24, −6, −4, −2, 0 h before and 2, 4, 6, 24, 48, 72, 96, 168, 336 and 504 h after ESWT. Plasma concentrations of interleukin 1 beta (IL‐1β), IL‐1 receptor antagonist (IL‐1RA), IL‐2, IL‐4, IL‐6, IL‐10, IL‐15, interferon gamma (IFN‐γ), soluble toll‐like receptor 2 (sTLR2) and tumour necrosis factor alpha (TNF‐α) were measured to assess the effects of ESWT on these mediators. Results: Baseline concentrations of inflammatory mediators did not change substantially during the week prior to ESWT. Plasma concentrations of five inflammatory factors changed following ESWT. IL‐1β and IL‐6 were significantly down‐regulated (P<0.01), while TNF‐α, IL‐1RA and TLR2 were significantly up‐regulated (P<0.01). The remaining cytokines were not significantly affected by ESWT. Main limitations: This study was performed in a small number of sedentary, healthy pasture‐kept horses using a single dose of ESWT applied to a single location. Additional studies are necessary to determine the effect of ESWT on inflammatory mediators in athletic horses undergoing treatment for musculoskeletal injuries. Conclusions: Plasma concentrations of TNF‐α, IL‐1β, IL‐1RA, IL‐6 and TLR2 were significantly affected by ESWT, and deserve further investigation as possible biomarkers of ESWT.
- 20 July 2018
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 41 (6) , 825-837
Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3‐hydroxylidocaine, monoethylglycinexylidide, and 4‐hydroxylidocaine in horse
Abstact: Intravenous (iv), subcutaneous (sq), and topical (tp) lidocaine was administered to six horses in a cross‐over, randomized design study. Samples were collected for up to 72 hr. Compartmental models were used to investigate the pharmacokinetics of (LD) and its metabolites 3‐hydroxylidocaine (3‐OH), 4‐hydroxylidocaine (4‐OH), and monoethylglycinexylidide (MEGX). Metabolites 3‐OH and 4‐OH were present in conjugated forms, whereas LD and metabolite MEXG were present primarily in the un‐conjugated form. Plasma concentrations of LD after iv administration (100 mg) were described by three‐compartment model with an additional three compartments to describe the elimination of metabolites. Median (range) elimination micro‐constants (Ke) for LD, 3‐OH, 4‐OH, and MEXG were 4.12 (2.62–6.23), 1.25 (1.10–2.15), 1.79 (1.22–2.39), and 1.69 (1.03–1.99)/hr, respectively. Median (range) values of alpha (t½α), beta (t½β), and gamma (t½γ) half‐lives were 0.08 (0.07–0.13), 0.57 (0.15–1.25), and 4.11 (0.52–7.36) hr. Plasma concentrations of LD after sq (200 mg) administration were described by absorption and two‐compartment elimination model. The median (range) of the LD absorption half‐life (t½ab) was 0.47 (0.29–0.61) hr. TheKefor LD, 3‐OH, 4‐OH, and MEXG was 3.91 (1.48–9.25), 1.00 (0.78–1.08), 1.76 (0.96–2.11), and 1.13 (0.69–1.33)/hr. The median (range) oft½αandt½βwas 0.15 (0.06–0.27) and 3.04 (2.53–6.39) hr. Plasma concentrations of LD after tp (400 mg) application were described by one‐compartment model with at½abof 8.49 (5.16–11.80) hr. TheKefor LD, 3‐OH, and MEXG was 0.24 (0.10–0.81), 0.41 (0.08–0.93), and 0.38 (0.26–1.14)/hr.
- 20 July 2018
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 41 (6) , 825-837
Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3‐hydroxylidocaine, monoethylglycinexylidide, and 4‐hydroxylidocaine in horse
Abstact: Intravenous (iv), subcutaneous (sq), and topical (tp) lidocaine was administered to six horses in a cross‐over, randomized design study. Samples were collected for up to 72 hr. Compartmental models were used to investigate the pharmacokinetics of (LD) and its metabolites 3‐hydroxylidocaine (3‐OH), 4‐hydroxylidocaine (4‐OH), and monoethylglycinexylidide (MEGX). Metabolites 3‐OH and 4‐OH were present in conjugated forms, whereas LD and metabolite MEXG were present primarily in the un‐conjugated form. Plasma concentrations of LD after iv administration (100 mg) were described by three‐compartment model with an additional three compartments to describe the elimination of metabolites. Median (range) elimination micro‐constants (Ke) for LD, 3‐OH, 4‐OH, and MEXG were 4.12 (2.62–6.23), 1.25 (1.10–2.15), 1.79 (1.22–2.39), and 1.69 (1.03–1.99)/hr, respectively. Median (range) values of alpha (t½α), beta (t½β), and gamma (t½γ) half‐lives were 0.08 (0.07–0.13), 0.57 (0.15–1.25), and 4.11 (0.52–7.36) hr. Plasma concentrations of LD after sq (200 mg) administration were described by absorption and two‐compartment elimination model. The median (range) of the LD absorption half‐life (t½ab) was 0.47 (0.29–0.61) hr. TheKefor LD, 3‐OH, 4‐OH, and MEXG was 3.91 (1.48–9.25), 1.00 (0.78–1.08), 1.76 (0.96–2.11), and 1.13 (0.69–1.33)/hr. The median (range) oft½αandt½βwas 0.15 (0.06–0.27) and 3.04 (2.53–6.39) hr. Plasma concentrations of LD after tp (400 mg) application were described by one‐compartment model with at½abof 8.49 (5.16–11.80) hr. TheKefor LD, 3‐OH, and MEXG was 0.24 (0.10–0.81), 0.41 (0.08–0.93), and 0.38 (0.26–1.14)/hr.
- Open Access
- 14 January 2018
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 41 (3) , 384-392
Pharmacokinetics, disposition, and plasma concentrations of dimethyl sulfoxide (DMSO) in the horse following topical, oral, and intravenous administration
Compartmental models were used to investigate the pharmacokinetics of intravenous (i.v.), oral (p.o.), and topical (TOP) administration of dimethyl sulfoxide (DMSO). The plasma concentration–time curve following a 15‐min i.v. infusion ofDMSOwas described by a two‐compartment model. Median and range of alpha (t1/2α) and beta (t1/2β) half‐lives were 0.029 (0.026–0.093) and 14.1 (6.6–16.4) hr, respectively. Plasma concentration–time curves ofDMSOfollowing p.o. andTOPadministration were best described by one‐compartment absorption and elimination models. Following the p.o. administration, median absorption (t1/2ab) and elimination (t1/2e) half‐lives were 0.15 (0.01–0.77) and 15.5 (8.5–25.2) hr, respectively. The plasma concentrations ofDMSOwere 47.4–129.9 μg/ml, occurring between 15 min and 4 hr. The fractional absorption (F) during a 24‐hr period was 47.4 (22.7–98.1)%. FollowingTOPadministrations, the mediant1/2abandt1/2ewere 1.2 (0.49–2.3) and 4.5 (2.1–11.0) hr, respectively. Plasma concentrations were 1.2–8.2 μg/ml occurring at 2–4 hr. Fractional absorption followingTOPadministration was 0.48 (0.315–4.4)% of the dose administered. Clearance (Cl) ofDMSOfollowing the i.v. administration was 3.2 (2.2–6.7) ml hr−1 kg−1. The corrected clearances (ClF) for p.o. andTOPadministrations were 2.9 (1.1–5.5) and 4.5 (0.52–18.2) ml hr−1 kg−1.
- 14 January 2018
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 41 (3) , 384-392
Open AccessPharmacokinetics, disposition, and plasma concentrations of dimethyl sulfoxide (DMSO) in the horse following topical, oral, and intravenous administration
Compartmental models were used to investigate the pharmacokinetics of intravenous (i.v.), oral (p.o.), and topical (TOP) administration of dimethyl sulfoxide (DMSO). The plasma concentration–time curve following a 15‐min i.v. infusion ofDMSOwas described by a two‐compartment model. Median and range of alpha (t1/2α) and beta (t1/2β) half‐lives were 0.029 (0.026–0.093) and 14.1 (6.6–16.4) hr, respectively. Plasma concentration–time curves ofDMSOfollowing p.o. andTOPadministration were best described by one‐compartment absorption and elimination models. Following the p.o. administration, median absorption (t1/2ab) and elimination (t1/2e) half‐lives were 0.15 (0.01–0.77) and 15.5 (8.5–25.2) hr, respectively. The plasma concentrations ofDMSOwere 47.4–129.9 μg/ml, occurring between 15 min and 4 hr. The fractional absorption (F) during a 24‐hr period was 47.4 (22.7–98.1)%. FollowingTOPadministrations, the mediant1/2abandt1/2ewere 1.2 (0.49–2.3) and 4.5 (2.1–11.0) hr, respectively. Plasma concentrations were 1.2–8.2 μg/ml occurring at 2–4 hr. Fractional absorption followingTOPadministration was 0.48 (0.315–4.4)% of the dose administered. Clearance (Cl) ofDMSOfollowing the i.v. administration was 3.2 (2.2–6.7) ml hr−1 kg−1. The corrected clearances (ClF) for p.o. andTOPadministrations were 2.9 (1.1–5.5) and 4.5 (0.52–18.2) ml hr−1 kg−1.
- Open Access
- 17 February 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 94
Identification of sample donor by 24-plex short tandem repeat in a post-race equine plasma containing dexamethasone
Background: Animal sport such as horseracing is tainted with drug abuse as are human sports. Treatment of racehorses on race day with therapeutic medications in most cases is banned, and thus, it is essential to monitor the illicit use of drugs in the racing horse to maintain integrity of racing, ensure fair competition and protect the health, safety and welfare of the horse, jockeys and drivers. In the event of a dispute over the identity of the sample donor, if the regulator can provide evidence that the DNA genotype profile of the post-race sample matched that of the alleged donor, then the potential drug violation case might be easily resolved without legal challenges. Case description: We present a case study of a racehorse sample that tested positive for dexamethasone in a post-race plasma sample in Pennsylvania (PA) but the result was challenged by the trainer of the horse. Dexamethasone is a synthetic glucocorticoid widely used in the management of musculoskeletal problems in horses but its presence in the horse during competition is banned by the PA Racing Commissions. The presence of dexamethasone in the post-competition plasma sample was confirmed using liquid chromatography-tandem mass spectrometry. However, this finding was challenged by the trainer of the horse alleging that the post-race sample was not collected from his/her horse and thus petitioned the Commission to be absolved of any wrong-doing. To resolve the dispute, a DNA test was ordered by the PA Racing Commission to identify the correct donor of the dexamethasone positive sample. For this purpose, a 24-plex short tandem repeat analysis to detect 21 equine markers and three human markers was employed. The results indicated that all the samples tested had identical DNA profiles and thus, it was concluded that the samples were collected from the same horse and that the probability of drawing a false conclusion was approximately zero (1.5 × 10-15). Conclusions: The plasma sample confirmed for the presence of dexamethasone was collected from the alleged horse.
- 17 February 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3 (1) , 94
Open AccessIdentification of sample donor by 24-plex short tandem repeat in a post-race equine plasma containing dexamethasone
Background: Animal sport such as horseracing is tainted with drug abuse as are human sports. Treatment of racehorses on race day with therapeutic medications in most cases is banned, and thus, it is essential to monitor the illicit use of drugs in the racing horse to maintain integrity of racing, ensure fair competition and protect the health, safety and welfare of the horse, jockeys and drivers. In the event of a dispute over the identity of the sample donor, if the regulator can provide evidence that the DNA genotype profile of the post-race sample matched that of the alleged donor, then the potential drug violation case might be easily resolved without legal challenges. Case description: We present a case study of a racehorse sample that tested positive for dexamethasone in a post-race plasma sample in Pennsylvania (PA) but the result was challenged by the trainer of the horse. Dexamethasone is a synthetic glucocorticoid widely used in the management of musculoskeletal problems in horses but its presence in the horse during competition is banned by the PA Racing Commissions. The presence of dexamethasone in the post-competition plasma sample was confirmed using liquid chromatography-tandem mass spectrometry. However, this finding was challenged by the trainer of the horse alleging that the post-race sample was not collected from his/her horse and thus petitioned the Commission to be absolved of any wrong-doing. To resolve the dispute, a DNA test was ordered by the PA Racing Commission to identify the correct donor of the dexamethasone positive sample. For this purpose, a 24-plex short tandem repeat analysis to detect 21 equine markers and three human markers was employed. The results indicated that all the samples tested had identical DNA profiles and thus, it was concluded that the samples were collected from the same horse and that the probability of drawing a false conclusion was approximately zero (1.5 × 10-15). Conclusions: The plasma sample confirmed for the presence of dexamethasone was collected from the alleged horse.
- 1 January 2014
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 108, 9-22
Interleukin-1β inhibits synthesis of 5-lipooxygenase in lipopolysaccharide-stimulated equine whole blood
- 1 January 2014
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 108, 9-22
Interleukin-1β inhibits synthesis of 5-lipooxygenase in lipopolysaccharide-stimulated equine whole blood